Tocilizumab

BreastfeedingPediatric
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Efavirenz, Fesoterodine, Fingolimod, Infliximab, Lurasidone, Paricalcitol, Pazopanib, Typhoid Vaccine, Yellow Fever Vaccine

PREGNANCY CATEGORY: N/A
Based on animal data, may cause fetal harm

Under investigation for treating COVID-19

RISK OF SERIOUS INFECTIONS

See full prescribing information for complete boxed warning.

Anaphylactoid reactions/Anaphylaxis 

(2017): Machado SH+, Expert Opin Drug Saf 16(4), 493 [REVIEW]

(2016): Farah Z+, Biologics 10, 59

(2011): Koike T+, Ann Rheum Dis 70(12), 2148

(2010): Tanaka T+, Expert Rev Clin Immunol 6(6), 843

(2008): Yokota S+, Lancet 371(9617), 998

Angioedema 

(2017): Machado SH+, Expert Opin Drug Saf 16(4), 493 [REVIEW]

Candidiasis 

(2015): Hammoudeh M+, Int J Rheumatol May, Epub1%

Cellulitis 

(2017): Ishiguro N+, Mod Rheumatol 27(2), 2171%

(2017): Lin CT+, J Microbiol Immunol Infect Jul, Epub ahead of print

(2017): Machado SH+, Expert Opin Drug Saf 16(4), 493 [REVIEW]

(2015): Brunner HI+, Ann Rheum Dis 74(6), 11101%

(2014): Nakashima Y+, Drug Des Devel Ther 8, 913

(2013): Weinblatt ME+, Arthritis Care Res (Hoboken) 65(3), 3621%

(2012): Yazici Y+, Ann Rheum Dis 71(2), 198 (2 cases)

(2011): Koike T+, Ann Rheum Dis 70(12), 2148

(2008): Genovese MC+, Arthritis Rheum 58(10), 29681%

DRESS syndrome 

(2017): Zuelgaray E+, Ann Intern Med 167(2), 141

Erythroderma 

(2009): Nakamura M+, Eur J Dermatol 19(3), 273

Facial edema 

(2016): Song ST+, Clin Exp Rheumatol 34(6 Suppl 102), S64

Folliculitis 

(2010): Illei GG+, Arthritis Rheum 62(2), 542

Herpes zoster 

(2017): Ishiguro N+, Mod Rheumatol 27(2), 2171%

(2017): Machado SH+, Expert Opin Drug Saf 16(4), 493 [REVIEW]

(2016): Farah Z+, Biologics 10, 59

(2015): Horneff G, Expert Opin Drug Saf 14(7), 1111 [REVIEW]

(2011): Koike T+, Ann Rheum Dis 70(12), 2148

(2011): Roux C+, J Rheumatol 38(2), 399 (ophthalmic)

(2009): Nishimoto N+, Ann Rheum Dis 68(10), 1580

(2008): Genovese MC+, Arthritis Rheum 58(10), 2968<1%

Hypersensitivity 

(2018): Garcia-Neuer M+, J Allergy Clin Immunol Pract 6(1), 90 (vocal fold motion)

(2017): Jones G+, J Rheumatol 44(2), 142

(2015): Galvao VR+, J Allergy Clin Immunol Pract 3(2), 175 [REVIEW]

(2011): Bannwarth B+, Expert Opin Drug Saf 10(1), 123 [REVIEW]

(2011): Koike T+, Ann Rheum Dis 70(12), 2148

(2010): Tanaka T+, Expert Rev Clin Immunol 6(6), 843

Jaundice 

(2015): McLaughlin M+, Expert Opin Drug Saf 14(3), 429 [REVIEW]

Lymphoma 

(2015): McLaughlin M+, Expert Opin Drug Saf 14(3), 429 [REVIEW]

Malignancies 

(2017): Ishiguro N+, Mod Rheumatol 27(2), 2171%

(2011): Koike T+, Ann Rheum Dis 70(12), 2148

Melanoma 

(2013): Finet A+, Clin Rheumatol 32(2), 277

Palmar–plantar toxicity 

(2014): Sparsa L+, Rev Med Interne (French) 35(9), 613

Pemphigus 

(2017): Hayashida MZ+, An Bras Dermatol 92(4), 591

Peripheral edema <2%

(package insert)

Photosensitivity 

(2016): Hamada K+, Eur J Dermatol 26(5), 503

Pruritus (itching) 

(2008): Plushner SL, Ann Pharmacother 42(11), 1660 [REVIEW]

Psoriasis 

(2018): Hayakawa M+, Rheumatol Int Oct, Epub ahead of print [REVIEW] (1 case)

(2018): Sehgal R+, Clin Med Res Apr, Epub ahead of print

(2012): Wendling D+, J Rheumatol 39(3), 657

(2010): Laurent S+, Br J Dermatol 163(6), 1364

Rash 2%

(2019): Bouajina E+, Clin Rheumatol Dec, Epub ahead of print (14 cases)

(2017): Lai JM+, Zhonghua Er Ke Za Zhi (Chinese) 55(11), 830Pediatric

(2016): Teitsma XM+, Arthritis Res Ther 18(1), 211 [REVIEW]

(2015): Brunner HI+, Ann Rheum Dis 74(6), 11102%

(2015): McLaughlin M+, Expert Opin Drug Saf 14(3), 429 [REVIEW]

(2011): Campbell L+, Rheumatology (Oxford) 50(3), 552 [REVIEW]

(2008): Emery P+, Ann Rheum Dis 67(11), 1516

(2008): Plushner SL, Ann Pharmacother 42(11), 1660 [REVIEW]

Sarcoidosis 

(2017): Perez-De-Lis M+, Expert Opin Drug Saf 16(11), 1255 [REVIEW]

Scabies 

(2011): Baccouche K+, Joint Bone Spine 78(4), 402

Septic–toxic shock 

(2018): Shirai T+, Medicine (Baltimore) 97(23) [REVIEW]

Toxicity 

(2010): Yoshiki R+, J Eur Acad Dermatol Venereol 24(4), 495

Urticaria 

(2017): Machado SH+, Expert Opin Drug Saf 16(4), 493 [REVIEW]

(2015): McLaughlin M+, Expert Opin Drug Saf 14(3), 429 [REVIEW]

Varicella zoster 

(2017): Machado SH+, Expert Opin Drug Saf 16(4), 493 [REVIEW]

Vasculitis 

(2017): Perez-De-Lis M+, Expert Opin Drug Saf 16(11), 1255 [REVIEW]

Aphthous stomatitis 

(2013): Samimi M+, Ann Dermatol Venereol (French) 140(2), 120 (2 cases)

Mucosal ulceration 

(2016): Emmi G+, Semin Arthritis Rheum 46(1), e1 (exacerbation)

(2016): Vitiello G+, Semin Arthritis Rheum 46(2), e9

Oral candidiasis 

(2010): Illei GG+, Arthritis Rheum 62(2), 542

Oral ulceration 2%

(2017): Machado SH+, Expert Opin Drug Saf 16(4), 493 [REVIEW]

Oropharyngeal pain 

(2015): Brunner HI+, Ann Rheum Dis 74(6), 11104%

Stomatitis (oral mucositis) <2%

(package insert)

Cardiotoxicity 

(2017): Ishiguro N+, Mod Rheumatol 27(2), 217<1%

(2015): McLaughlin M+, Expert Opin Drug Saf 14(3), 429 [REVIEW]

(2011): Koike T+, Ann Rheum Dis 70(12), 2148

Chest pain 

(2015): McLaughlin M+, Expert Opin Drug Saf 14(3), 429 [REVIEW]

Hypertension 6%

(2019): Elmedany SH+, Clin Rheumatol March, Epub ahead of print

(2016): Flaig T+, J Clin Pharm Ther 41(6), 718 [REVIEW] (passim)

(2016): Song ST+, Clin Exp Rheumatol 34(6 Suppl 102), S64

(2010): Tanaka T+, Expert Rev Clin Immunol 6(6), 843

Palpitation 

(2015): McLaughlin M+, Expert Opin Drug Saf 14(3), 429 [REVIEW]

Thromboembolism 

(2015): McLaughlin M+, Expert Opin Drug Saf 14(3), 429 [REVIEW]

Anorexia 

(2008): Ohsugi Y+, Expert Opin Biol Ther 8(5), 669

Chills 

(2017): Lai JM+, Zhonghua Er Ke Za Zhi (Chinese) 55(11), 830Pediatric

Dysesthesia 

(2017): Machado SH+, Expert Opin Drug Saf 16(4), 493 [REVIEW] (scalp)

Fever (pyrexia) 

(2011): Koike T+, Ann Rheum Dis 70(12), 2148

Headache 7%

(2017): Machado SH+, Expert Opin Drug Saf 16(4), 493 [REVIEW]

(2015): Brunner HI+, Ann Rheum Dis 74(6), 11108%

(2015): McLaughlin M+, Expert Opin Drug Saf 14(3), 429 [REVIEW]

(2011): van Duin D+, Emerg Infect Dis 17(4), 754

(2010): Tanaka T+, Expert Rev Clin Immunol 6(6), 843

(2008): Emery P+, Ann Rheum Dis 67(11), 1516

(2008): Plushner SL, Ann Pharmacother 42(11), 1660 [REVIEW]

Leukoencephalopathy 

(2009): Kobayashi K+, Intern Med 48(15), 1307

Neurotoxicity 

(2011): Koike T+, Ann Rheum Dis 70(12), 2148

(2009): Nishimoto N+, Ann Rheum Dis 68(10), 1580

Vertigo / dizziness 3%

(2015): McLaughlin M+, Expert Opin Drug Saf 14(3), 429 [REVIEW]

Alanine aminotransferase (ALT) increased 6%

(2017): Canete JD+, Expert Opin Biol Ther Jun, Epub ahead of print [REVIEW]

(2017): Genovese MC+, Arthritis Rheumatol 69(9), 17518%

(2017): Machado SH+, Expert Opin Drug Saf 16(4), 493 [REVIEW]

(2016): Kivitz A+, Rheumatol Ther 3(2), 29138%

(2015): Hammoudeh M+, Int J Rheumatol May, Epub1%

(2015): McLaughlin M+, Expert Opin Drug Saf 14(3), 429 [REVIEW]

(2014): Nakashima Y+, Drug Des Devel Ther 8, 913

(2014): Stoll ML+, Pediatr Rheumatol Online J 12, 13

(2013): Dougados M+, Ann Rheum Dis 72(1), 431%

(2008): Genovese MC+, Arthritis Rheum 58(10), 29684%

Aspartate aminotransferase (AST) increased 

(2017): Canete JD+, Expert Opin Biol Ther 17(9), 1089 [REVIEW]

(2017): Genovese MC+, Arthritis Rheumatol 69(9), 17514%

(2017): Machado SH+, Expert Opin Drug Saf 16(4), 493 [REVIEW]

(2014): Nakashima Y+, Drug Des Devel Ther 8, 913

Hypercholesterolemia  

(2019): Bouajina E+, Clin Rheumatol Dec, Epub ahead of print (18 cases)

(2019): Elmedany SH+, Clin Rheumatol March, Epub ahead of print

(2017): Caporali R+, Clin Exp Rheumatol 35(6), 919

(2017): Machado SH+, Expert Opin Drug Saf 16(4), 493 [REVIEW]

(2016): Flaig T+, J Clin Pharm Ther 41(6), 718 [REVIEW] (passim)

(2015): Hammoudeh M+, Int J Rheumatol May, Epub3%

Hyperlipidemia  

(2019): Elmedany SH+, Clin Rheumatol March, Epub ahead of print

(2012): Psenak O+, Z Rheumatol 71(5), 420

(2010): Febbraio MA+, Clin Pharmacol Ther 87 (4), 396

(2010): Jones G, Expert Rev Clin Immunol 6 (2), 189

(2008): Genovese MC+, Arthritis Rheum 58(10), 296823%

(2008): Plushner SL, Ann Pharmacother 42(11), 1660 [REVIEW]

Hypertransaminasemia (transaminitis) 

(2019): Bouajina E+, Clin Rheumatol Dec, Epub ahead of print (15 cases)

(2019): Elmedany SH+, Clin Rheumatol March, Epub ahead of print

Hypertriglyceridemia  

(2019): Bouajina E+, Clin Rheumatol Dec, Epub ahead of print (17 cases)

(2016): Flaig T+, J Clin Pharm Ther 41(6), 718 [REVIEW] (passim)

(2015): Hammoudeh M+, Int J Rheumatol May, Epub1%

Hypothyroidism <2%

(package insert)

Weight gain <2%

(2010): Febbraio MA+, Clin Pharmacol Ther 87 (4), 396

Abdominal pain 2%

(2015): Brunner HI+, Ann Rheum Dis 74(6), 11103%

Black stools 

(2011): Koike T+, Ann Rheum Dis 70(12), 2148

Diarrhea 

(2017): Machado SH+, Expert Opin Drug Saf 16(4), 493 [REVIEW]

(2015): Brunner HI+, Ann Rheum Dis 74(6), 11104%

Gastritis 1%

(package insert)

Gastroenteritis 

(2017): Canete JD+, Expert Opin Biol Ther 17(9), 1089 [REVIEW]

(2017): Machado SH+, Expert Opin Drug Saf 16(4), 493 [REVIEW]

(2016): Yokota S+, Ann Rheum Dis 75(9), 16547%

(2014): Nakashima Y+, Drug Des Devel Ther 8, 913

(2011): Koike T+, Ann Rheum Dis 70(12), 2148

(2008): Yokota S+, Lancet 371(9617), 998

Gastrointestinal bleeding 

(2017): Machado SH+, Expert Opin Drug Saf 16(4), 493 [REVIEW]

(2014): Stoll ML+, Pediatr Rheumatol Online J 12, 13

(2008): Yokota S+, Lancet 371(9617), 998

Gastrointestinal disorder 

(2019): Bouajina E+, Clin Rheumatol Dec, Epub ahead of print (3 cases)

Gastrointestinal perforation 

(2019): Giles JT+, Arthritis Rheumatol Aug, Epub ahead of print

(2017): Canete JD+, Expert Opin Biol Ther 17(9), 1089 [REVIEW]

(2017): Ishiguro N+, Mod Rheumatol 27(2), 217<1%

(2015): McLaughlin M+, Expert Opin Drug Saf 14(3), 429 [REVIEW]

(2012): Ruderman EM, Rheumatology (Oxford) 51, 37

(2011): Bannwarth B+, Expert Opin Drug Saf 10(1), 123 [REVIEW]

(2011): Gout T+, Clin Rheumatol 30(11), 1471 [REVIEW]

(2011): Koike T+, Ann Rheum Dis 70(12), 2148

(2010): Tanaka T+, Expert Rev Clin Immunol 6(6), 843

Gastrointestinal ulceration <2%

(package insert)

Hepatitis 

(2013): Alfreijat M+, Rheumatology (Oxford) 52(7), 1340

Hepatotoxicity 

(2018): Shirai T+, Medicine (Baltimore) 97(23) [REVIEW]

(2017): Anger F+, Rheumatology (Oxford) 56(9), 1628

(2017): Genovese MC+, Arthritis Rheumatol 69(9), 1751 (severe / 7 cases)

(2017): Ishiguro N+, Mod Rheumatol 27(2), 2177%

(2017): Machado SH+, Expert Opin Drug Saf 16(4), 493 [REVIEW]

(2016): Yokota S+, Ann Rheum Dis 75(9), 16547%

(2015): Hammoudeh M+, Int J Rheumatol May, Epub10%

(2015): Wang G+, Int J Gen Med 8, 187

(2014): Machado-Alba JE+, Rev Panam Salud Publica 36(6), 39610%

(2014): Navarro G+, Semin Arthritis Rheum 43(4), 458

(2014): Stoll ML+, Pediatr Rheumatol Online J 12, 13

(2011): Hagiwara K, Endoscopy 43(10), 928

(2011): Iwasa T+, Endoscopy 43(1), 70

(2010): Storage SS+, Korean J Intern Med 25 (1), 1

(2009): Nishimoto N+, Ann Rheum Dis 68(10), 1580

(2008): Plushner SL, Ann Pharmacother 42(11), 1660 [REVIEW]

Nausea 

(2018): Emery P+, Rheumatology (Oxford) Dec, Epub ahead of print7%

(2016): Teitsma XM+, Arthritis Res Ther 18(1), 211 [REVIEW]

(2015): Brunner HI+, Ann Rheum Dis 74(6), 11106%

(2011): Campbell L+, Rheumatology (Oxford) 50(3), 552 [REVIEW]

Pancreatitis 

(2017): Perez-De-Lis M+, Expert Opin Drug Saf 16(11), 1255 [REVIEW]

(2016): Flaig T+, J Clin Pharm Ther 41(6), 718 [REVIEW]

Vomiting  

(2015): Brunner HI+, Ann Rheum Dis 74(6), 11102%

Urinary tract infection 

(2017): Canete JD+, Expert Opin Biol Ther 17(9), 1089 [REVIEW]

(2017): Ishiguro N+, Mod Rheumatol 27(2), 217<1%

(2010): Illei GG+, Arthritis Rheum 62(2), 542

Anemia 

(2008): Ohsugi Y+, Expert Opin Biol Ther 8(5), 669

Dyslipidemia 

(2015): Wang G+, Int J Gen Med 8, 187

Eosinophilia 

(2017): Perez-De-Lis M+, Expert Opin Drug Saf 16(11), 1255 [REVIEW]

Hemoglobin decreased 

(2019): Elmedany SH+, Clin Rheumatol (March) Epub ahead of print

Hemotoxicity 

(2017): Martis N+, Joint Bone Spine 84(3), 369 (hypofibrinogenemia)

(2012): Matsuoka M+, Int J Hematol 96(6), 781

Leukocytopenia (leukopenia) <2%

(2017): Caporali R+, Clin Exp Rheumatol 35(6), 919

(2017): Kaneshiro S+, Mod Rheumatol 27(1), 42 (1 case) (with tacrolimus)

(2016): Devauchelle-Pensec V+, Ann Rheum Dis 75(8), 1506

(2014): Machado-Alba JE+, Rev Panam Salud Publica 36(6), 39612%

(2011): Koike T+, Ann Rheum Dis 70(12), 2148

Lymphopenia (lymphocytopenia) 

(2017): Kaneshiro S+, Mod Rheumatol 27(1), 42 (3 cases) (with tacrolimus)

(2014): Stoll ML+, Pediatr Rheumatol Online J 12, 13

Macrophage activation syndrome 

(2017): Machado SH+, Expert Opin Drug Saf 16(4), 493 [REVIEW]

Neutropenia 

(2019): Bouajina E+, Clin Rheumatol Dec, Epub ahead of print (7 cases)

(2019): Elmedany SH+, Clin Rheumatol March, Epub ahead of print

(2018): Opoka-Winiarska V+, Clin Rheumatol Apr, Epub ahead of print

(2017): Canete JD+, Expert Opin Biol Ther 17(9), 1089 [REVIEW]

(2017): Espinoza F+, J Rheumatol 44(6), 84419%

(2017): Machado SH+, Expert Opin Drug Saf 16 (4), 493 [REVIEW]

(2017): Perez-De-Lis M+, Expert Opin Drug Saf 16(11), 1255 [REVIEW]

(2016): Albattal BM, Ann Saudi Med 36(3), 190

(2016): Devauchelle-Pensec V+, Ann Rheum Dis 75(8), 1506 (transient)

(2016): Farah Z+, Biologics 10, 59

(2016): Kivitz A+, Rheumatol Ther 3(2), 2913% (grade 3 or 4) (transient)

(2015): Horneff G, Expert Opin Drug Saf 14(7), 1111 [REVIEW]

(2015): McLaughlin M+, Expert Opin Drug Saf 14(3), 429 [REVIEW]

(2014): Loricera J+, Clin Exp Rheumatol 32(3 Suppl 82), s79 [REVIEW]

(2014): Stoll ML+, Pediatr Rheumatol Online J 12, 13

(2013): Uda H+, Scand J Rheumatol 42(3), 247 (60 cases)

(2012): De Benedetti F+, N Engl J Med 367(25), 2385

(2011): Bannwarth B+, Expert Opin Drug Saf 10(1), 123 [REVIEW]

(2011): Koike T+, Ann Rheum Dis 70(12), 2148

(2010): Storage SS+, Korean J Intern Med 25 (1), 1

(2008): Genovese MC+, Arthritis Rheum 58(10), 29684% (grade 3)

(2008): Plushner SL, Ann Pharmacother 42(11), 1660 [REVIEW]

Sepsis 

(2016): Farah Z+, Biologics 10, 59

(2011): Koike T+, Ann Rheum Dis 70(12), 2148

Thrombocytopenia 

(2016): Albattal BM, Ann Saudi Med 36(3), 190

Infusion-related reactions 

(2015): Horneff G, Expert Opin Drug Saf 14(7), 1111 [REVIEW]

(2015): McLaughlin M+, Expert Opin Drug Saf 14(3), 429 [REVIEW]

(2014): Yokota S+, J Rheumatol 41(4), 759

Infusion-site reactions 

(2015): McLaughlin M+, Expert Opin Drug Saf 14(3), 429 [REVIEW]

(2009): Prescrire Int 18 (103), 198

Injection-site edema 

(2014): Nakashima Y+, Drug Des Devel Ther 8, 913

Injection-site erythema 

(2014): Nakashima Y+, Drug Des Devel Ther 8, 913

Injection-site hemorrhage 

(2014): Nakashima Y+, Drug Des Devel Ther 8, 913

Injection-site pain 

(2014): Nakashima Y+, Drug Des Devel Ther 8, 913

Injection-site pruritus 

(2014): Nakashima Y+, Drug Des Devel Ther 8, 913

Arthralgia 

(2015): McLaughlin M+, Expert Opin Drug Saf 14(3), 429 [REVIEW]

(2014): Nakashima Y+, Drug Des Devel Ther 8, 913

(2013): Uda H+, Scand J Rheumatol 42(3), 247

(2011): Koike T+, Ann Rheum Dis 70(12), 2148

Asthenia / fatigue 

(2008): Ohsugi Y+, Expert Opin Biol Ther 8(5), 669

Back pain 

(2009): Nishimoto N+, Ann Rheum Dis 68(10), 1580

Fractures 

(2011): Koike T+, Ann Rheum Dis 70(12), 2148

(2009): Nishimoto N+, Ann Rheum Dis 68 (10), 1580

Cataract 

(2009): Nishimoto N+, Ann Rheum Dis 68(10), 1580

Conjunctivitis <2%

(package insert)

Optic neuropathy 

(2017): Stone JH+, N Engl J Med 377(4), 317

Papilledema 

(2017): Burstzyn L+, Clin Exp Rheumatol 35(1), 149Pediatric (with prednisone)

Uveitis 

(2015): Horneff G, Expert Opin Drug Saf 14(7), 1111 [REVIEW]

Otitis media 

(2010): Illei GG+, Arthritis Rheum 62(2), 542

Glomerulonephritis 

(2013): Matsuo Y+, Rheumatology (Oxford) 52(7), 1341

Nephrolithiasis <2%

(package insert)

Nephrotoxicity 

(2007): Matsuyama M+, Intern Med 46(11), 771

Pyelonephritis 

(2011): Koike T+, Ann Rheum Dis 70(12), 2148

(2010): Illei GG+, Arthritis Rheum 62(2), 542

(2009): Nishimoto N+, Ann Rheum Dis 68(10), 1580

Bronchitis 3%

(2017): Machado SH+, Expert Opin Drug Saf 16(4), 493 [REVIEW]

(2016): Yokota S+, Ann Rheum Dis 75(9), 16546%

(2015): Brunner HI+, Ann Rheum Dis 74(6), 11101%

(2011): Koike T+, Ann Rheum Dis 70(12), 2148

(2009): Nishimoto N+, Ann Rheum Dis 68(10), 1580

(2008): Yokota S+, Lancet 371(9617), 998

Cough <2%

(2015): Brunner HI+, Ann Rheum Dis 74(6), 11104%

Dyspnea <2%

(package insert)

Influenza 

(2016): Yokota S+, Ann Rheum Dis 75(9), 16547%

(2015): Hammoudeh M+, Int J Rheumatol May, Epub1%

(2013): Wendling D+, Joint Bone Spine 80(2), 225

Nasopharyngitis 7%

(2017): Machado SH+, Expert Opin Drug Saf 16(4), 493 [REVIEW]

(2016): Yokota S+, Ann Rheum Dis 75(9), 16545%

(2015): Brunner HI+, Ann Rheum Dis 74(6), 111012%

(2011): Campbell L+, Rheumatology (Oxford) 50(3), 552 [REVIEW]

(2011): van Duin D+, Emerg Infect Dis 17(4), 754

(2010): Tanaka T+, Expert Rev Clin Immunol 6(6), 843

(2008): Plushner SL, Ann Pharmacother 42(11), 1660 [REVIEW]

Pharyngitis 

(2018): Opoka-Winiarska V+, Clin Rheumatol Apr, Epub ahead of print

(2017): Machado SH+, Expert Opin Drug Saf 16(4), 493 [REVIEW]

(2016): Yokota S+, Ann Rheum Dis 75(9), 16545%

(2015): Brunner HI+, Ann Rheum Dis 74(6), 11104%

Pneumonia 

(2020): Gouveia PA+, Cureus 12(2), e6982 (1 case)

(2017): Canete JD+, Expert Opin Biol Ther 17(9), 1089 [REVIEW]

(2017): Ishiguro N+, Mod Rheumatol 27(2), 2171%

(2017): Jones G+, J Rheumatol 44(2), 142

(2017): Lin CT+, J Microbiol Immunol Infect Jul, Epub ahead of print

(2017): Machado SH+, Expert Opin Drug Saf 16(4), 493 [REVIEW]

(2015): Brunner HI+, Ann Rheum Dis 74(6), 11102%

(2014): Nakashima Y+, Drug Des Devel Ther 8, 913

(2013): Weinblatt ME+, Arthritis Care Res (Hoboken) 65(3), 3621%

(2011): Ikegawa K+, Intern Med 50(19), 2191 (with methotrexate)

(2011): Koike T+, Ann Rheum Dis 70(12), 2148

(2009): Nishimoto N+, Ann Rheum Dis 68(10), 1580

(2008): Genovese MC+, Arthritis Rheum 58(10), 2968<1%

Pneumonitis 

(2011): van Duin D+, Emerg Infect Dis 17(4), 754

Pneumothorax 

(2011): Koike T+, Ann Rheum Dis 70(12), 2148

(2009): Nishimoto N+, Ann Rheum Dis 68(10), 1580

Pulmonary toxicity 

(2017): Chen J+, Expert Opin Biol Ther 17(3), 265

(2017): Ishiguro N+, Mod Rheumatol 27(2), 2171%

(2014): Roubille C+, Semin Arthritis Rheum 43(5), 613 [REVIEW]

(2012): Kawashiri SY+, Rheumatol Int 32(12), 4023 (fatal)Fatal (exacerbation)

(2011): Honda H+, Mod Rheumatol 21(6), 660 (with etanercept)

Respiratory disorder 

(2019): Bouajina E+, Clin Rheumatol Dec, Epub ahead of print (3 cases)

Rhinitis 

(2015): Brunner HI+, Ann Rheum Dis 74(6), 11104%

Sinusitis 

(2010): Illei GG+, Arthritis Rheum 62 (2), 542

Tuberculosis 

(2011): Koike T+, Ann Rheum Dis 70(12), 2148

Upper respiratory tract infection 7%

(2018): Emery P+, Rheumatology (Oxford) Dec, Epub ahead of print7%

(2018): Opoka-Winiarska V+, Clin Rheumatol Apr, Epub ahead of print

(2017): Machado SH+, Expert Opin Drug Saf 16(4), 493 [REVIEW]

(2016): Flaig T+, J Clin Pharm Ther 41(6), 718 [REVIEW] (passim)

(2016): Yokota S+, Ann Rheum Dis 75(9), 165417%

(2015): Brunner HI+, Ann Rheum Dis 74(6), 11107%

(2015): Hammoudeh M+, Int J Rheumatol May, Epub3%

(2015): McLaughlin M+, Expert Opin Drug Saf 14(3), 429 [REVIEW]

(2011): Campbell L+, Rheumatology (Oxford) 50(3), 552 [REVIEW]

(2011): van Duin D+, Emerg Infect Dis 17(4), 754

(2010): Illei GG+, Arthritis Rheum 62(2), 542

(2010): Tanaka T+, Expert Rev Clin Immunol 6(6), 843

Adverse effects 

(2020): Zhang C+, Lancet Neurol 19(5), 39161%

(2019): Haraoui B+, Rheumatol Ther March, Epub ahead of print

(2019): Isaacs JD+, Rheumatol Adv Pract 3(1), eCollection6% (serious) (± combination therapy with conventional synthetic disease-modifying antirheumatic drugs (DMARDs))

(2018): Nakaoka Y+, Ann Rheum Dis 77(3), 348 (serious / 1 case)

(2017): Caporali R+, Clin Exp Rheumatol 35(6), 91929%

(2017): Notario Ferreira I+, Reumatol Clin 13(2), 78

(2016): Al-Mayouf SM+, Int J Rheum Dis 19(6), 600Pediatric

(2016): Albattal BM, Ann Saudi Med 36(3), 19011%

(2016): Regent A+, J Rheumatol 43(8), 1547

(2016): Yokota S+, Ann Rheum Dis 75(9), 165469%

(2015): Tarkiainen M+, Rheumatology (Oxford) 54(7), 1170

(2014): Machado-Alba JE+, Rev Panam Salud Publica 36(6), 396

(2013): Gabay C+, Lancet 381(9877), 154112%

(2012): Imagawa T+, Mod Rheumatol 22(1), 109

(2008): Genovese MC+, Arthritis Rheum 58(10), 29687%

Allergic reactions 

(2015): McLaughlin M+, Expert Opin Drug Saf 14(3), 429 [REVIEW]

Cancer 

(2015): McLaughlin M+, Expert Opin Drug Saf 14(3), 429 [REVIEW]

Death 

(2019): Isaacs JD+, Rheumatol Adv Pract 3(1), eCollection (1 case) (± combination therapy with conventional synthetic disease-modifying antirheumatic drugs (DMARDs))

(2018): Ogata A+, Mod Rheumatol 28(1), 76 (1 case)

(2017): Ishiguro N+, Mod Rheumatol 27(2), 2171%

(2016): Khanna D+, Lancet 387(10038), 2630 (1 case)

(2015): McLaughlin M+, Expert Opin Drug Saf 14(3), 429 [REVIEW]

(2012): Kawashiri SY+, Rheumatol Int 32(12), 4023

Infection 

(2019): Giles JT+, Arthritis Rheumatol Aug, Epub ahead of print

(2018): Iannone F+, Clin Rheumatol 37(2), 315

(2018): Ogata A+, Mod Rheumatol 28(1), 76

(2017): Ishiguro N+, Mod Rheumatol 27(2), 21712%

(2017): Jones G+, J Rheumatol 44(2), 142

(2017): Machado SH+, Expert Opin Drug Saf 16(4), 493 [REVIEW]

(2016): Khanna D+, Lancet 387(10038), 263016%

(2016): Kivitz A+, Rheumatol Ther 3(2), 2914% (serious)

(2016): Teitsma XM+, Arthritis Res Ther 18(1), 211 [REVIEW] (skin and respiratory)

(2016): Yokota S+, Ann Rheum Dis 75(9), 165441%

(2015): Brunner HI+, Ann Rheum Dis 74(6), 1110

(2015): Horneff G, Expert Opin Drug Saf 14(7), 1111 [REVIEW]

(2015): McLaughlin M+, Expert Opin Drug Saf 14(3), 429 [REVIEW]

(2015): Wang G+, Int J Gen Med 8, 187

(2014): Dhillon S, BioDrugs 28(1), 75 [REVIEW]

(2014): Nakashima Y+, Drug Des Devel Ther 8, 913

(2014): Navarro G+, Semin Arthritis Rheum 43(4), 458

(2014): Stoll ML+, Pediatr Rheumatol Online J 12, 13

(2014): Yokota S+, J Rheumatol 41(4), 759

(2013): Dougados M+, Ann Rheum Dis 72(1), 43

(2013): Milin M+, Joint Bone Spine 80(2), 221

(2013): Nguyen MT+, BMJ Case Rep 2013 (3 cases)

(2013): Weinblatt ME+, Arthritis Care Res (Hoboken) 65(3), 362

(2012): Bykerk VP+, Ann Rheum Dis 71(12), 1950

(2012): De Benedetti F+, N Engl J Med 367(25), 2385

(2012): Yazici Y+, Ann Rheum Dis 71(2), 198

(2011): Bannwarth B+, Expert Opin Drug Saf 10(1), 123 [REVIEW]

(2011): Burmester GR+, Ann Rheum Dis 70(5), 7553%

(2011): Inayama M+, Kansenshogaku Zasshi (Japanese) 85(5), 523

(2011): Koike T+, Ann Rheum Dis 70(12), 2148

(2010): Hirabayashi Y+, Rheumatol Int 30(8), 1041

(2010): Jones G, Expert Rev Clin Immunol 6 (2), 189

(2010): Nishimoto N+, Mod Rheumatol 20(3), 222

(2010): Tanaka T+, Expert Rev Clin Immunol 6(6), 843

(2008): Emery P+, Ann Rheum Dis 67(11), 1516

(2008): Genovese MC+, Arthritis Rheum 58(10), 29687%

(2008): Plushner SL, Ann Pharmacother 42(11), 1660 [REVIEW]

(2008): Smolen JS+, Lancet 371, 987

(2007): Nishimoto N+, Ann Rheum Dis 66(9), 1162

(2006): Ding C+, Rev Recent Clin Trials 1(3), 193 [REVIEW]



Visit Informa

Click on the DRUG REVIEW ARTICLE tab (above) to see a review of tocilizumab in the treatment of juvenile idiopathic arthritis in the Taylor & Francis journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)

Adverse reactions attributed to entire drug class Anti-interleukin-6 receptor monoclonal antibody

Neutropenia 

(2019): Andres E+, J Clin Med 8(9), E1351 [REVIEW]

Adverse reactions attributed to entire drug class Biologic

Psoriasis 

(2020): Afach S+, Br J Dermatol May, Online ahead of print [REVIEW]

(2020): Montolio Chiva L+, Reumatol Clin Mar, Epub ahead of print [REVIEW]

Vasculitis 

(2016): Gutierrez-Gonzalez LA, Curr Rheumatol Rep 18(7), 39 [REVIEW]

Infusion-related reactions 

(2016): Al-Mayouf SM+, Int J Rheum Dis 19(6), 60034%Pediatric

Uveitis 

(2020): Klein A+, ACR Open Rheumatol 2(1), 376%

Adverse effects 

(2020): Roberti R+, Curr Med Res Opin Jun, Online ahead of print

(2016): Al-Mayouf SM+, Int J Rheum Dis 19(6), 60035%Pediatric

Infection 

(2020): Klein A+, ACR Open Rheumatol 2(1), 373%

Adverse reactions attributed to entire drug class Biologic disease-modifying antirheumatic drug (bDMARD)

Lymphocytosis 

(2020): Barbieri MA+, J Clin Med 9(4), E12279% (serious)

Neutropenia 

(2020): Barbieri MA+, J Clin Med 9(4), E122713% (serious)

Uveitis 

(2020): Barbieri MA+, J Clin Med 9(4), E12277% (serious)

Adverse effects 

(2020): Cometi L+, J Clin Med 9(5), E1310

(2020): Martínez-López-de-Castro N+, Eur J Rheumatol 7(2), 53-59

Infection 

(2020): Barbieri MA+, J Clin Med 9(4), E122722%

Adverse reactions attributed to entire drug class COVID-19 putative drug

Cutaneous adverse reaction  

(2020): Tursen U+, Dermatol Ther May, Epub ahead of print [REVIEW]

Cardiovascular adverse effect 

(2020): Carpenter A+, Front Cardiovasc Med 7, 85 [REVIEW]

(2020): Giudicessi JR+, Mayo Clin Proc May, Online ahead of print [REVIEW]

(2020): Naksuk N+, Eur Heart J Acute Cardiovasc Care May, Epub ahead of print [REVIEW]

(2020): Sarayani A+, Res Social Adm Pharm Apr, Epub ahead of print [REVIEW]

(2020): Zhang D+, Zhongguo Zhong Yao Za Zhi (Chinese) 45(10), 2275-2286 [REVIEW]

Neuropsychiatric disturbances 

(2020): García CAC+, Gen Hosp Psychiatry Jun, Online ahead of print [REVIEW]

Gastrointestinal disorder 

(2020): Sun J+, Clin Pharmacol Ther Apr, Epub ahead of print23%

Hepatic disorder 

(2020): Sun J+, Clin Pharmacol Ther Apr, Epub ahead of print14%

Thrombocytopenia 

(2020): Nham E+, Infect Chemother Apr, Epub ahead of print

Adverse effects 

(2020): Favilli A+, J Matern Fetal Neonatal Med Jun, Online ahead of print [REVIEW]

(2020): Griffiths G+, Trials 21(1), 544

(2020): Patil VM+, Life Sci May, Epub ahead of print [REVIEW]

(2020): Rhodes NJ+, medRxiv Jun, Preprint

(2020): Sun J+, Clin Pharmacol Ther Apr, Epub ahead of print38%

(2020): Svensson M, Lakartidningen (Swedish) Apr, 117

(2020): Wen CY+, Zhonghua Nei Ke Za Zhi (Chinese) May, Epub ahead of print

(2020): Zhong H+, Pharmacol Res Apr, Epub ahead of print [REVIEW]

Page last updated 06/25/2020

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top